Restricted accessLetterFirst published online 2010-12
Renal Dosimetry: Ready for Biological Equivalent Dose? Response to Medical Internal Radiation Dose and European Association of Nuclear Medicine Committee Letters
BaroneR, Borson-ChazotF, ValkemaRet al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med, 2005; 46,suppl:99S.
4.
BodeiL, CremonesiM, FerrariMet al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imag, 2008; 35:1847.
5.
WesselsBW, KonijnenbergMW, DaleRGet al. MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med, 2008; 49:1884.
6.
WesselsBW, SgourosG. Renal Dosimetry. Cancer Biother Radiopharm, 2010; 25:597.
7.
LassmannM, StrigariL, BardiesM. Dosimetry is alive and well. Cancer Biother Radiopharm 2010;25:593. 8. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med, 1999; 40:37S.
8.
SiegelJA, ThomasSR, StubbsJBet al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med, 1999; 40:37S.
9.
BuijsWCAM, SiegelJA, BoermanOC, CorstensFHM. Absolute organ activity estimated by five different methods of background correction. J Nucl Med, 1998; 39:2167.
10.
HindorfC, ChittendenS, CauserLet al. Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm, 2007; 22:130.
11.
VoitEO, YiPN. Comparison of isoeffect relationships in radiotherapy. Bull Math Biol, 1990; 52:657.
12.
HowellRW, GodduSM, RaoDV. Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. J Nucl Med, 1994; 35:1861.
13.
O'DonoghueJ. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm, 2004; 19:378.
